68Ga-PSMA PET/CT在前列腺癌生化复发患者中的应用:一项前瞻性两中心研究
该前瞻性两中心研究纳入70例前列腺癌根治性治疗后生化复发患者,行68Ga-PSMA PET/CT检测复发灶并评估对治疗管理的影响。68Ga-PSMA PET/CT在37例(53%)患者中检出复发灶;PSA≤0.5 ng/mL时检出率为22%,PSA>0.5 ng/mL时为83%。15/69例(22%)因结果明确改变治疗管理,另15/69例(22%)指导了治疗选择。
要点
- 68Ga-PSMA PET/CT在生化复发前列腺癌中检出复发灶37/70例(53%)。
- PSA≤0.5 ng/mL检出率22%,PSA>0.5 ng/mL检出率83%。
- 15/69例(22%)因结果明确改变管理,另15/69例(22%)指导治疗选择。
核心结论
- 68Ga-PSMA PET/CT在大部分生化复发前列腺癌患者中检出病灶,低PSA水平(<0.5 ng/mL)检出率明显低于既往回顾性研究报告值,但检出率随PSA水平升高而提高。
研究设计与样本
- 前瞻性两中心研究,纳入前列腺癌根治性治疗后生化复发患者70例,每例接受68Ga-PSMA PET/CT,评估基于结果的病人管理变化。
主要发现
- 64例(91%)患者接受根治性前列腺切除术,其中17例(24%)因首次生化复发接受挽救性放疗;6例(9%)接受放疗作为主要治疗。
- 68Ga-PSMA PET/CT在37例(53%)患者中检出复发疾病。
- PSA≤0.5 ng/mL时检出率为22%,PSA>0.5 ng/mL时为83%。
- PSA 0.2-0.3 ng/mL组21例中4例(16%)、0.31-0.4 ng/mL组9例中4例(44%)、0.41-0.5 ng/mL组1例中0例、0.51-1 ng/mL组10例中7例(70%)、>1 ng/mL组25例中22例(88%)观察到68Ga-PSMA病理性摄取。
- PSMA阳性患者的前列腺特异性抗原(PSA)显著高于PSMA阴性患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE OF THE REPORT: The aim of this study was to prospectively investigate the detection rate of Ga-PSMA PET/CT in biochemical recurrence (BCR) of prostate cancer and its impact on patient management. MATERIALS AND METHODS: Patients with BCR after curatively intended treatment of prostate cancer were included. Each patient underwent a Ga-PSMA PET/CT. Changes in patient management based on the results of Ga-PSMA PET/CT were assessed. RESULTS: Seventy patients were included. Sixty-four patients (91%) had radical prostatectomy, of whom 17 patients (24%) received salvage radiation therapy due to first biochemical relapse. Six patients (9%) underwent radiation therapy as the primary treatment. Ga-PSMA PET/CT detected recurrent disease in 37 patients (53%). The detection rate was 22% for prostate-specific antigen (PSA) levels up to 0.5 ng/mL compared with 83% for PSA levels greater than 0.5 ng/mL. Pathological uptake of Ga-PSMA was observed in 4 (16%) of 21, 4 (44%) of 9, 0 of 1, 7 (70%) of 10, and 22 (88%) of 25 patients with PSA levels from 0.2 to 0.3 ng/mL, 0.31 to 0.4 ng/mL, 0.41 to 0.5 ng/mL, 0.51 to 1 ng/mL, and greater than 1 ng/mL, respectively. Prostate-specific antigen was significantly higher in PSMA-positive patients than in PSMA-negative patients. In 15 (22%) of 69 patients, the results caused a definite change in patient management, and in another 15 (22%) of 69 patients, Ga-PSMA PET/CT guided the choice of treatment. CONCLUSIONS: Ga-PSMA PET/CT detects lesions in a large proportion of patients with BCR. Detection rates at low PSA levels (<0.5 ng/mL) were notably below the values reported in previous retrospective studies; however, detection rates improved with increasing PSA levels.
引用
- Zacho HD, Nielsen JB, Dettmann K, et al. 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study. Clin Nucl Med. 2018. PMID: 29916917. doi:10.1097/RLU.0000000000002169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。